Literature DB >> 29142146

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Mike P Wattjes1,2, Martijn T Wijburg2,3, Jeroen van Eijk4, Stephan Frequin5, Bernard M J Uitdehaag3, Frederik Barkhof2,6, Clemens Warnke7,8, Joep Killestein3.   

Abstract

BACKGROUND AND
OBJECTIVE: Natalizumab-associated progressive multifocal leukoencephalopathy (NTZ-PML) patients may show imaging signs suggestive of inflammation at diagnosis ('inflammatory PML'), reminiscent of PML-immune reconstitution inflammatory syndrome (PML-IRIS). We investigated the imaging characteristics of inflammatory NTZ-PML lesions and PML-IRIS to determine differentiating and overlapping features.
METHODS: We scored the presence, localisation and pattern of imaging characteristics of inflammation on brain MRI scans of inflammatory NTZ-PML patients. The imaging characteristics were followed up until the occurrence of PML-IRIS.
RESULTS: Ten out of the 44 NTZ-PML patients included showed signs suggestive of inflammation at the time of diagnosis. The inflammation pattern at diagnosis was similar to the pattern seen at PML-IRIS, with contrast enhancement representing the most frequent sign of inflammation (90% at diagnosis, 100% at PML-IRIS). However, the severity of inflammation differed, with absence of swelling and low frequency of perilesional oedema (10%) at diagnosis, as compared with the PML-IRIS stage (40%).
CONCLUSION: Patterns of inflammation at the time of PML diagnosis and at the PML-IRIS stage overlap but differ in their severity of inflammation. This supports histopathological evidence that the inflammation seen at both stages of the same disease shares a similar underlying pathophysiology, representing the immune response to the JC virus to a variable extend. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  magnetic resonance imaging; multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy

Mesh:

Substances:

Year:  2017        PMID: 29142146     DOI: 10.1136/jnnp-2017-316886

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

1.  Four cases of natalizumab-related PML: a less severe course in extended interval dosing?

Authors:  Cristina Scarpazza; Nicola De Rossi; Giulietta Tabiadon; Maria Vittoria Turrini; Simonetta Gerevini; Ruggero Capra
Journal:  Neurol Sci       Date:  2019-06-07       Impact factor: 3.307

2.  The Effect of Intravenous Methylprednisolone on Recurrent Exacerbation in Hematologic Malignancy-associated Progressive Multifocal Leukoencephalopathy.

Authors:  Ryutaro Nakamura; Akihiro Kitamura; Takahito Tsukamoto; Ryota Tamura; Nobuhiro Ogawa; Isamu Yamakawa; Hyoh Kim; Michihiro Kawai; Mitsuru Sanada; Makoto Urushitani
Journal:  Intern Med       Date:  2020-11-23       Impact factor: 1.271

3.  Treatment of natalizumab-associated PML with filgrastim.

Authors:  Dusan Stefoski; Roumen Balabanov; Rasha Waheed; Michael Ko; Igor J Koralnik; Fabian Sierra Morales
Journal:  Ann Clin Transl Neurol       Date:  2019-04-08       Impact factor: 4.511

Review 4.  Fifty Years of JC Polyomavirus: A Brief Overview and Remaining Questions.

Authors:  Abigail L Atkinson; Walter J Atwood
Journal:  Viruses       Date:  2020-09-01       Impact factor: 5.048

5.  Case Report: Central Nervous System Immune Reconstitution Inflammatory Syndrome Related to Bacterial Meningitis.

Authors:  Mengyan Hu; Sanxin Liu; Danli Lu; Yi Zhong; Dafan Yu; Wei Qiu; Zhengqi Lu; Bingjun Zhang
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

Review 6.  Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.

Authors:  Kazuhiro Ishii; Fumiko Yamamoto; Shinsuke Homma; Yoshinori Okada; Kazuo Nakamichi; Masayuki Saijo; Akira Tamaoka
Journal:  BMC Neurol       Date:  2019-10-31       Impact factor: 2.474

7.  Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.

Authors:  Manel Alleg; Morgane Solis; Seyyid Baloglu; François Cotton; Philippe Kerschen; Bertrand Bourre; Guido Ahle; Jean-Pierre Pruvo; Xavier Leclerc; Patrick Vermersch; Caroline Papeix; Élisabeth Maillart; Caroline Houillier; Cécile Moluçon Chabrot; Béatrice Claise; Sandra Malak; Guillaume Martin-Blondel; Fabrice Bonneville; Alexis Caulier; Jean-Pierre Marolleau; Jérôme Tamburini Bonnefoy; Philippe Agape; Céline Kennel; Xavier Roussel; Adrien Chauchet; Jérôme De Seze; Samira Fafi-Kremer; Stéphane Kremer
Journal:  Eur Radiol       Date:  2020-11-06       Impact factor: 5.315

8.  CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments.

Authors:  Raphael Bernard-Valnet; Xavier Moisset; Nicolas Maubeuge; Mathilde Lefebvre; Jean-Christophe Ouallet; Mathilde Roumier; Christine Lebrun-Frenay; Jonathan Ciron; Damien Biotti; Pierre Clavelou; Bertrand Godeau; Renaud A Du Pasquier; Guillaume Martin-Blondel
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.